Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Other Accumulated Expenses (2022 - 2025)

Vivos Therapeutics has reported Other Accumulated Expenses over the past 4 years, most recently at $850000.0 for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 211.36% to $850000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $850000.0 through Dec 2025, up 211.36% year-over-year, with the annual reading at $850000.0 for FY2025, 211.36% up from the prior year.
  • Other Accumulated Expenses was $850000.0 for Q4 2025 at Vivos Therapeutics, down from $987000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $1.0 million in Q2 2025 and troughed at $127000.0 in Q1 2023.
  • The 4-year median for Other Accumulated Expenses is $273000.0 (2024), against an average of $396000.0.
  • Year-over-year, Other Accumulated Expenses tumbled 55.68% in 2023 and then surged 572.19% in 2025.
  • A 4-year view of Other Accumulated Expenses shows it stood at $145000.0 in 2022, then surged by 36.55% to $198000.0 in 2023, then soared by 37.88% to $273000.0 in 2024, then surged by 211.36% to $850000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Other Accumulated Expenses are $850000.0 (Q4 2025), $987000.0 (Q3 2025), and $1.0 million (Q2 2025).